oral semaglutide 50 mg Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Oral GLP-1 Medication Helps Patients

as well as the hippocampus

This biological shiftrather than willpower aloneaccounts for why GLP-1 therapy produces different results than traditional calorie-counting approaches

Thus, preliminary data from a phase 1b trial showed that use of cagrilintide and semaglutide in obese subjects resulted in greater weight loss than semaglutide alone, 17Percentage versus 10Percentage after 20 weeks [5]

Between December 2025 and January 2026, both of these MDLs gained new plaintiffs

22 : 540544 Jope RS

This Isnt Just a Petition, Its a Public Record The nonprofit officially submitted all 27,000+ signatures and 400+ comments in formal letters to the FDA and the USPTO, asking for: To the FDA requesting an action from the following: Allow regulated compounding when no affordable alternative exists Fast-track generic GLP-1 approvals Advocate for insurance coverage Pressure big pharma to lower prices To the USPTO , requesting they address the impact of evergreening patents that extend exclusivity and limit market competition